Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
PT Diagnos Laboratorium Utama Tbk delivers comprehensive medical laboratory services across Indonesia. The company offers a wide range of diagnostic tests, including clinical pathology services covering hematology, hemostasis, clinical chemistry, urinalysis, biomolecular analysis, immunology, and microbiology. It also performs anatomical pathology for the detailed examination of tissues and body fluids. Furthermore, PT Diagnos specializes in advanced genomics testing, such as non-invasive prenatal screening (NIPT) and preimplantation genetic testing for both aneuploidy and monogenic diseases. Beyond its core laboratory offerings, the company provides convenient home-based health check-ups, tailored corporate wellness programs, and specialized COVID-19 testing. Its broader involvement extends to supporting various healthcare initiatives and infrastructure, including maintaining specialized biological banks (e.g., eye, blood, sperm, and organ banks) and pharmacy warehousing, in collaboration with both public and private sector entities. Established in 2007, the company's headquarters are located in Jakarta Pusat, Indonesia.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,